3 results
The aim of the study is twofold. The first is the impact of the investigational drugs and the registered product on safety, tolerability and the release of vessels studied and compared. The second is the speed with which the investigational drugs…
Primary end point• Progression-free survival (PFS) per ICR central assessmentSecondary end point• Objective response rate (ORR)• Disease control rate (DCR)• Overall survival (OS)• PFS according to Investigator assessment of radiologic images•…
This clinical trial is an open-label extension trial of the main study SENSCISTM (1199.214) and 1199-0340 to further evaluate the safety of long term treatment with nintedanib in patients with scleroderma related lung fibrosis.Also, in this trial,…